¼¼°èÀÇ ¼Ò¾Æ¿ë ÀǾàǰ ¹× ¹é½Å ½ÃÀå
Pediatric Drugs and Vaccines
»óǰÄÚµå : 1513885
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 292 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,156,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,469,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼Ò¾Æ¿ë ÀǾàǰ ¹× ¹é½Å ¼¼°è ½ÃÀåÀº 2030³â±îÁö 1,567¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â¿¡ 1,047¾ï ´Þ·¯·Î ÃßÁ¤µÈ ¼Ò¾Æ¿ë ÀǾàǰ°ú ¹é½Å ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 1,567¾ï ´Þ·¯¿¡ À̸£°í, ºÐ¼® ±â°£ 2023-2030³âÀÇ CAGRÀº 5.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÄÁÁê°ÔÀÌÆ® ±â¼úÀº CAGR 7.1%·Î ¼ºÀåÀ» Áö¼ÓÇϰí, ºÐ¼® ±â°£ Á¾·á ½Ã 520¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶óÀÌºê °¨¼è ±â¼ú ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 6.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 282¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ ¼Ò¾Æ¿ë ÀǾàǰ°ú ¹é½Å ½ÃÀåÀº 2023³â 282¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 354¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ 2023-2030³âÀÇ CAGRÀº 9.9%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.0%¿Í 6.4%·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼Ò¾Æ¿ë ÀǾàǰ ¹× ¹é½Å - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ

¼Ò¾Æ¿ë ÀǾàǰ°ú ¹é½ÅÀº À¯¾Æ±âºÎÅÍ »çÃá±â±îÁö ¾î¸°ÀÌÀÇ °Ç°­°ú º¹Áö¿¡ ƯȭµÈ ÀǾàǰ ¾÷°è¿¡¼­ Áß¿äÇÑ ºÎºÐÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÀǾàǰ ¹× ¿¹¹æ Á¢Á¾Àº ¾ÈÀü, È¿´É ¹× ÀûÀýÇÑ º¹¿ë·®À» º¸ÀåÇϸ鼭 ¾î¸° ȯÀÚ Æ¯À¯ÀÇ »ý¸®Àû ¿ä±¸¿¡ ºÎÀÀÇϵµ·Ï Ưº°È÷ ó¹æµË´Ï´Ù. ¼Ò¾Æ¿ë ÀǾàǰÀº °¨¿°, ¸¸¼º Áúȯ, ¿µ¾ç °áÇÌÁõ, ±Þ¼º Áúȯ µî ´Ù¾çÇÑ Ä¡·á ¿µ¿ªÀ» ´Ù·ì´Ï´Ù. ¹é½ÅÀº È«¿ª, º¼°Å¸®, dzÁø, ¼Ò¾Æ¸¶ºñ µî »ý¸íÀ» À§ÇùÇÒ ¼ö ÀÖ´Â ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ ¸é¿ªÀ» Á¦°øÇÔÀ¸·Î½á ¸¶Âù°¡Áö·Î Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¼Ò¾Æ¿ë ÀǾàǰ ¹× ¹é½ÅÀÇ °³¹ß ¹× ½ÂÀÎ °úÁ¤¿¡´Â ȯÀÚ Áý´ÜÀÇ Ãë¾à¼ºÀ» °í·ÁÇÏ¿© ¾ö°ÝÇÑ ¾ÈÀü ±âÁØÀ» ÃæÁ·Çϱâ À§ÇÑ ¾ö°ÝÇÑ ÀÓ»ó½ÃÇè ¹× ±ÔÁ¦ ´ç±¹ÀÇ °ËÅä°¡ Æ÷ÇԵ˴ϴÙ.

ÀϺΠµ¿Çâ°ú Çõ½ÅÀº ¼Ò¾Æ¿ë ÀǾàǰ°ú ¹é½ÅÀÇ »óȲÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù. Áß¿äÇÑ µ¿Çâ Áß Çϳª´Â °³º° ȯÀÚÀÇ À¯ÀüÀÚ ±¸¼º¿¡ µû¶ó Ä¡·á¸¦ Á¶Á¤Çϰí, Ä¡·á ¼ºÀûÀ» Çâ»ó½Ã۰í, ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ´Â ¸ÂÃãÇü ÀÇ·á°¡ Áß¿äÇÏ´Ù´Â °ÍÀÔ´Ï´Ù. »ý¸í °øÇÐÀÇ Áøº¸´Â COVID-19 ÆÒµ¥¹Í¿¡¼­ ÁÖ¸ñ¹ÞÀº mRNA ¹é½Å°ú °°Àº »õ·Î¿î ¹é½Å Ç÷§ÆûÀÇ °³¹ß·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ç÷§ÆûÀº ½Å¼ÓÇÑ °³¹ß°ú ³ôÀº È¿À²¼ºÀ» ±â´ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇÑ ¹øÀÇ ÁÖ»ç·Î ¿©·¯ Áúº´À» ¿¹¹æÇϰí ÄÄÇöóÀÌ¾ð½º¿Í Á¢Á¾·üÀ» Çâ»ó½ÃŰ´Â È¥ÇÕ ¹é½Å¿¡ ´ëÇÑ °ü½Éµµ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¸ð¹ÙÀÏ Çコ ¿ëµµ°ú ¿ø°Ý ÀǷḦ Æ÷ÇÔÇÑ µðÁöÅÐ Çコ ±â¼úÀÇ ÅëÇÕÀº ȯÀÚ °ü¸®¿Í Ä¡·á ¿ä¹ý¿¡ ´ëÇÑ Ãæ°í¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼¼°è °Ç°­ ÀÌ´Ï¼ÅÆ¼ºê¿Í ÆÄÆ®³Ê½ÊÀº ÁßÀú¼Òµæ ±¹°¡¿¡¼­ Çʼö ¹é½Å°ú ÀǾàǰ¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

¼Ò¾Æ¿ë ÀǾàǰ°ú ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀº ¿©·¯ ¿äÀο¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù. µå·¡±×ÀÇ Á¦ÇüÈ­ ¹× Àü´Þ ½Ã½ºÅÛÀÇ ±â¼úÀû Áøº¸·Î, ¾ÃÀ» ¼ö ÀÖ´Â Á¤Á¦³ª ¿ëÇØ °¡´ÉÇÑ ½ºÆ®¸³ µî, º¸´Ù È¿°úÀûÀÌ°í ¼Ò¾Æ Ä£È­ÀûÀÎ ÀǾàǰÀÇ °³¹ßÀÌ °¡´ÉÇØÁö°í ÀÖ½À´Ï´Ù. õ½Ä, ´ç´¢º´ ¹× °£ÁúÀ» Æ÷ÇÔÇÑ ¼Ò¾ÆÀÇ ¸¸¼º ÁúȯÀÇ ÀÌȯÀ²ÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç Àå±â Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àû½ÃÀÇ ¿¹¹æÁ¢Á¾°ú ¿¹¹æÀÇ·á´ëÃ¥ÀÇ Á߿伺¿¡ ´ëÇÑ º¸È£ÀÚ³ª °£º´ÀÎÀÇ ÀǽÄÀÇ °íÁ¶°¡ ¿¹¹æÁ¢Á¾·üÀÇ »ó½ÂÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼Ò¾Æ °Ç°­ °ü¸® ÇÁ·Î±×·¥¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿Í ÀÚ±Ý Áö¿øÀÌ ½ÃÀå ¼ºÀåÀ» Å©°Ô µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦Àû ¿ì´ëÁ¶Ä¡¿¡ ÈûÀÔ¾î ¼Ò¾Æ ÀÓ»ó½ÃÇèÀÇ ¹üÀ§°¡ È®´ëµÇ°í ÀÖ´Â °Íµµ »õ·Ó°í Çõ½ÅÀûÀÎ Ä¡·áÀÇ µµÀÔÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ¹é½ÅÁ¢Á¾ Ä·ÆäÀÎÀ» ÅëÇØ Àü¿°º´ ¹Ú¸ê¿¡ ¼¼°èÀûÀ¸·Î ÁÖ·ÂÇϰí ÀÖ´Â °ÍÀÌ ¼Ò¾Æ¿ë ¹é½ÅÀÇ °³¹ß°ú À¯ÅëÀ» µÞ¹ÞÄ§ÇØ ¼¼°è ¾î¸°À̵éÀÇ °Ç°­»óÅ °³¼±À» È®½ÇÈ÷ Çϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÁÖ¸ñ 76»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Pediatric Drugs and Vaccines Market to Reach US$156.7 Billion by 2030

The global market for Pediatric Drugs and Vaccines estimated at US$104.7 Billion in the year 2023, is expected to reach US$156.7 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030. Conjugate Technology, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$52.0 Billion by the end of the analysis period. Growth in the Live Attenuated Technology segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$28.2 Billion While China is Forecast to Grow at 9.9% CAGR

The Pediatric Drugs and Vaccines market in the U.S. is estimated at US$28.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$35.4 Billion by the year 2030 trailing a CAGR of 9.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Pediatric Drugs and Vaccines - Key Trends and Drivers

Pediatric drugs and vaccines represent a crucial segment in the pharmaceutical industry, dedicated to the health and wellbeing of children from infancy through adolescence. These medications and immunizations are specifically formulated to address the unique physiological needs of young patients, ensuring safety, efficacy, and appropriate dosing. Pediatric drugs cover a broad spectrum of therapeutic areas, including infectious diseases, chronic illnesses, nutritional deficiencies, and acute conditions. Vaccines play an equally vital role by providing immunity against a range of potentially life-threatening diseases such as measles, mumps, rubella, polio, and more. The development and approval process for pediatric drugs and vaccines involve rigorous clinical trials and regulatory scrutiny to ensure they meet stringent safety standards, given the vulnerable nature of the patient population.

Several trends and innovations are shaping the landscape of pediatric drugs and vaccines. One significant trend is the increasing emphasis on personalized medicine, which tailors treatments based on the genetic makeup of individual patients, thus improving therapeutic outcomes and minimizing adverse effects. Advances in biotechnology are leading to the development of novel vaccine platforms, such as mRNA vaccines, which have gained prominence during the COVID-19 pandemic. These platforms offer the potential for rapid development and high efficacy. Additionally, there is a growing focus on combination vaccines, which protect against multiple diseases with a single injection, thereby improving compliance and coverage rates. The integration of digital health technologies, including mobile health applications and telemedicine, is enhancing patient management and adherence to treatment regimens. Moreover, global health initiatives and partnerships are instrumental in increasing access to essential vaccines and medications in low- and middle-income countries.

The growth in the pediatric drugs and vaccines market is driven by several factors. Technological advancements in drug formulation and delivery systems are enabling the development of more effective and child-friendly medications, such as chewable tablets and dissolvable strips. The rising incidence of chronic diseases in children, including asthma, diabetes, and epilepsy, is fueling demand for long-term therapeutic solutions. Increasing awareness among parents and caregivers about the importance of timely vaccinations and preventive healthcare measures is leading to higher immunization rates. Additionally, government initiatives and funding for pediatric healthcare programs are providing a significant boost to market growth. The expanding scope of pediatric clinical trials, driven by regulatory incentives, is accelerating the introduction of new and innovative treatments. Lastly, the global focus on eradicating infectious diseases through vaccination campaigns is propelling the development and distribution of pediatric vaccines, ensuring better health outcomes for children worldwide.

Select Competitors (Total 76 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â